Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1828)	1/12/2015 10:31:06 AM
From: Biotech Jim	Respond to of 1834

I had suggested to a colleague that a friend of hers try to go on the Elagolix trial. I am a big believer in this drug based on the Ph2 trials that NBIX performed. Unfortunately the friend was not allowed in the trial due to a potential drug-drug interaction. I also am eager to see the specific dosing data. I no longer hold NBIX, but did quite well on the stock.

To: Miljenko Zuanic who wrote (1828)	5/5/2015 1:06:25 PM
From: tuck	Read Replies (1) \| Respond to of 1834

At which scientific meeting might AbbVie disclose the numbers for Violet Petal? Either of you guys have any speculation regarding that? Obviously not ACOG, which is happening now, next ENDO is a year away . . . So my guess is ASRM in October. ASRM 2015 Annual Meeting Though the preliminary program didn't have a slot for abstract sessions that I saw, presumably there will be one. This is where earlier Elagolix data was presented in 2011. TIA & Cheers, Tuck